Phenyltoloxamine is an antihistamine with sedative and analgesic effects. It is available in combination with other drugs such as paracetamol. Phenyltoloxamine is a centrally active H1 receptor antagonist often supplied as a salt to improve aqueous solubility for oral formulations. Pharmacologically it produces H1 blockade that reduces histamine-mediated capillary permeability and vasodilation and crosses the blood brain barrier to produce sedation; analgesic synergy with paracetamol is attributed to central nervous system depressant effects and possible modulation of pain pathways. In formulation and development contexts attention is paid to salt form, crystalline habit, hygroscopicity, solubility profile, and compatibility with common excipients used in tablets and syrups. Key functional attributes relevant to manufacturing include thermal stability, pKa driven ionization behavior in physiological pH, and susceptibility to oxidative and N-dealkylation pathways under stressed conditions.
Parent: Phenyltoloxamine / Phenyltoloxamine Citrate
Parent: Phenyltoloxamine
Typical quality specifications for active substance batches and finished products set assay acceptance at high purity with common targets of 98.0 to 100.5 percent on a normalized basis, total related substances limit commonly 1.0 to 2.0 percent, and individual unspecified impurity limits commonly 0.05 to 0.5 percent depending on identity and toxicological qualification. Typical identified related compounds include N-demethylated and N-dealkylated metabolites, aromatic ring oxidation products, minor positional isomers and N-oxide derivatives; each is often limited to 0.1 to 0.5 percent by area% in chromatographic assays. Residual solvents are controlled in accordance with ICH Q3C limits, heavy metals typically below 10 to 20 ppm, and water content by Karl Fischer normally below 0.5 percent w/w for nonhygroscopic lots. Stability-indicating methods are used to quantify degradants after forced degradation studies and specification limits are set to ensure safety and efficacy throughout shelf life.
Phenyltoloxamine is used primarily for symptomatic relief of allergic conditions such as rhinitis and urticaria, for short term relief of pruritus, and as a sedative adjunct in some cold and analgesic combination products; when combined with acetaminophen it is used to treat symptoms of headache and minor pain while providing sedative and antihistaminic effects. Clinical use should follow product labeling and regulatory approvals for the specific formulation.
There is no single universal brand name for the phenyltoloxamine plus acetaminophen combination; formulations are marketed under different trade names in different countries and may be available only as generic combinations in some markets. To identify a specific brand, consult local formularies, national drug registries, or the product label in the target country.
Phenyltoloxamine acts primarily as an H1 histamine receptor antagonist, reducing histamine mediated vasodilation, increased vascular permeability and sensory nerve activation. Central H1 receptor blockade produces sedation. The compound may undergo metabolic N-dealkylation and other biotransformations; its analgesic contribution in combinations is considered pharmacodynamic synergy rather than a direct opioid like mechanism.
